{"id":"NCT03083665","sponsor":"UCB Biopharma SRL","briefTitle":"A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam in Subjects (>=16 to 80 Years of Age) With Partial Seizures With or Without Secondary Generalization","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-22","primaryCompletion":"2022-06-30","completion":"2022-06-30","firstPosted":"2017-03-20","resultsPosted":"2023-11-09","lastUpdate":"2024-06-11"},"enrollment":449,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Partial Seizures With or Without Secondary Generalization","Epilepsy"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Brivaracetam","otherNames":["Briviact"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"BRV 50 mg/day","type":"EXPERIMENTAL"},{"label":"BRV 200 mg/day","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to placebo (PBO) as adjunctive treatment in subjects (\\>=16 to 80 years of age) with partial seizures with or without secondary generalization despite current treatment with 1 or 2 concomitant antiepileptic drugs (AEDs) and to assess the safety and tolerability of BRV in subjects \\>= 16 years to 80 years of age.","primaryOutcome":{"measure":"Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"From start of the Treatment Period (Week 0) until Safety Visit (up to Week 18); only for OLTP- From last visit of Transition Period to beginning of MAP (up to 4 Years 10 Months)","effectByArm":[{"arm":"Placebo","deltaMin":58.4,"sd":null},{"arm":"BRV 50 mg/Day","deltaMin":57,"sd":null},{"arm":"BRV 200 mg/Day","deltaMin":60.1,"sd":null},{"arm":"Placebo to OLTP BRV","deltaMin":26.6,"sd":null},{"arm":"BRV 50 mg/Day to OLTP BRV","deltaMin":19.1,"sd":null},{"arm":"BRV 200 mg/Day to OLTP BRV","deltaMin":23,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":94,"countries":["China","Japan","Malaysia","Philippines","Singapore","Taiwan","Thailand"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":149},"commonTop":["Somnolence","Dizziness","Nasopharyngitis","Headache","Upper respiratory tract infection"]}}